News | Radiation Therapy | March 15, 2022

High-dose, targeted radiation of brain metastases affects memory less than more complex whole brain radiation therapy, and can be performed again if necessary

Above a certain size, individual brain metastases are often surgically removed with the help of microsurgical resection. In stereotactic radiosurgery (SRS), in contrast, they are usually treated with a single high-dose targeted radiation using cobalt-60-gamma radiation sources.

March 15, 2022 — Above a certain size, individual brain metastases are often surgically removed with the help of microsurgical resection. In stereotactic radiosurgery (SRS), in contrast, they are usually treated with a single high-dose targeted radiation using cobalt-60-gamma radiation sources. In contrast to whole brain radiation therapy (WBRT), this method is intended to expose only the tumor tissue to the high radiation dose and to spare the surrounding tissue. The German Institute for Quality and Efficiency in Health Care (IQWiG) now investigated the advantages and disadvantages of this single-dose SRS treatment in comparison with surgery and with WBRT in a benefit assessment.

The result: Compared with WBRT, SRS spares the patients’ memory performance. In addition, single-dose SRS requires only one treatment and can be performed again if the disease progresses. In the overall view of the study data, this results in a hint of greater benefit of SRS.

Compared with the surgical removal of a few metastases, no conclusions can be drawn for SRS due to a suspected publication bias – except that SRS is less invasive and can be performed on an outpatient basis. This is because the MD Anderson Cancer Center (Texas, United States) has withheld the results of a completed study for over ten years, although IQWiG and other stakeholders have made several intensive efforts to obtain the data.

SRS versus whole brain radiation therapy: less impairment of memory performance

The data basis is much better for the comparison of SRS with WBRT, as a total of six randomized controlled trials (RCTs) are available: five studies with moderate certainty of results and one study with high certainty of results. These studies provide a hint of greater benefit of SRS for memory performance as a subcomponent of cognitive functioning. Based on the available data, a reduction in survival time cannot be completely ruled out, but is not probable. The comparison remains open with regard to other components of cognitive functioning (e.g. speech fluency) as well as activities of daily living, side effects of therapy and health-related quality of life.

In principle, single-dose SRS offers the treatment-inherent advantages over WBRT that, with a single treatment (instead of ten to twenty), it requires much less effort for the patients and that it can be repeated, for example in the case of recurrence.

Decisive aspects: memory is less impaired and treatment is less time-consuming

It spares memory, is less invasive, repeatable and requires less effort: These advantages of SRS are decisive for IQWiG’s benefit assessment, even if side effects and quality of life cannot be sufficiently assessed. For seriously ill patients with brain metastases, these advantages weigh particularly heavily because of their usually short life expectancy. “Not least the very constructive comments on the preliminary report and the good exchange with the professional societies provided us with a deeper insight into patient preferences as well as clinical practice and confirmed our conclusion," says Stefan Sauerland, Head of the IQWiG Department of Non-Drug Interventions.

Weighing up all aspects, it remains unclear for both the comparison of SRS with WBRT and the comparison with resection to what extent a possibly shorter survival is accepted by the patients. When making a treatment decision, however, the most important aspects for the patients are symptom control with preservation of mental and physical abilities as well as the effort required.

For more information: https://www.iqwig.de/en/

Related content:

Burst of Radiation and Vesicles-based Immunotherapy Suppress Brain Cancer Growth

New PET Radiotracer Proven Safe in Imaging Malignant Brain Tumors

Focused Ultrasound Shows Promise Against Deadliest Brain Tumor

New Standardized Brain Tumor MRI Recommendations Announced


Related Content

News | Radiation Therapy

July 22, 2024 — RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from ...

Time July 22, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Digital Pathology

July 12, 2024 — AGFA HealthCare, a global leader in healthcare imaging management solutions, announced that Enterprise ...

Time July 12, 2024
arrow
News | Digital Pathology

July 12, 2024 — Diagnosing cancer and providing the personalized therapy it often requires, is a collaborative effort ...

Time July 12, 2024
arrow
Feature | Imaging Technology News - ITN

Be sure to check out the latest digital edition of Imaging Technology News (ITN), featuring the Mobile C-arm Systems ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 09, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
Feature | Radiology Business

ITN conducts a bi-monthly survey to its readers on a variety of topics, which is used to create the Last Read, a unique ...

Time July 08, 2024
arrow
Subscribe Now